RNA Avidity Biosciences Inc

$46.35

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

In the rapidly evolving biotech landscape, Avidity Biosciences stands out with its robust market cap of approximately $4.3 billion, reflecting strong investor confidence despite the absence of recent news. As the company approaches its earnings announcement on August 12, analysts are keenly observing its ability to meet the EPS estimate of $0.00, which aligns with the whisper number, suggesting stable expectations. The anticipated revenue of $1.49 million will be a critical indicator of Avidity's progress in advancing its innovative RNA-based therapies. Investors will be particularly interested in any strategic updates that could signal future growth trajectories or partnerships, as these could significantly impact market sentiment and the company's valuation.

Updated On 8/22/2025

About Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.

Website: https://www.aviditybiosciences.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1599901
Address
10975 N. TORREY PINES RD.,, #150, LA JOLLA, CA, US
Valuation
Market Cap
$3.20B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
2.25
Performance
EPS
$-2.89
Dividend Yield
—
Profit Margin
0.00%
ROE
-33.50%
Technicals
50D MA
$30.11
200D MA
$38.10
52W High
$56.00
52W Low
$21.51
Fundamentals
Shares Outstanding
120M
Target Price
$66.69
Beta
1.01

RNA EPS Estimates vs Actual

● Estimated
● Actual

RNA News & Sentiment

Aug 14, 2025 • Zacks Commentary NEUTRAL
Clene Inc. ( CLNN ) Reports Q2 Loss, Misses Revenue Estimates
Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 13, 2025 • Zacks Commentary NEUTRAL
Mersana Therapeutics, Inc. ( MRSN ) Reports Q2 Loss, Lags Revenue Estimates
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 12, 2025 • Zacks Commentary NEUTRAL
Fate Therapeutics ( FATE ) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 07, 2025 • Motley Fool SOMEWHAT-BULLISH
Avidity ( RNA ) Q2 Revenue Jumps 88%
Avidity Biosciences ( NASDAQ:RNA ) , a biotechnology firm developing RNA-targeted therapeutics for rare muscle diseases, reported its second-quarter 2025 results on August 7, 2025. The period featured sharply higher revenue ( GAAP ) at $3.8 million, well above the $1.49 million average analyst ...
Aug 07, 2025 • Zacks Commentary NEUTRAL
Iovance Biotherapeutics ( IOVA ) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 06, 2025 • Zacks Commentary NEUTRAL
Arcutis Biotherapeutics, Inc. ( ARQT ) Reports Q2 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Sentiment Snapshot

Average Sentiment Score:

0.183
50 articles with scored sentiment

Overall Sentiment:

Bullish

RNA Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.80
  • Estimate: $-0.78
  • Whisper: —
  • Surprise %: -2.5%
Nov 06, 2024
Sep 30, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $-0.65
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: 8.4%
Aug 09, 2024
Jun 30, 2024 (Post market)
0.14 Surprise
  • Reported EPS: $-0.65
  • Estimate: $-0.79
  • Whisper: —
  • Surprise %: 17.7%
May 09, 2024
Mar 31, 2024 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.79
  • Estimate: $-0.78
  • Whisper: —
  • Surprise %: -1.3%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.13 Surprise
  • Reported EPS: $-0.79
  • Estimate: $-0.66
  • Whisper: —
  • Surprise %: -19.7%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.06 Surprise
  • Reported EPS: $-0.71
  • Estimate: $-0.77
  • Whisper: —
  • Surprise %: 7.8%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.14 Surprise
  • Reported EPS: $-0.66
  • Estimate: $-0.80
  • Whisper: —
  • Surprise %: 17.5%
May 09, 2023
Mar 31, 2023 (Post market)
0.11 Surprise
  • Reported EPS: $-0.74
  • Estimate: $-0.85
  • Whisper: —
  • Surprise %: 12.9%
Feb 28, 2023
Dec 31, 2022 (Post market)
0.01 Surprise
  • Reported EPS: $-0.88
  • Estimate: $-0.89
  • Whisper: —
  • Surprise %: 1.1%

Financials